This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| BAM15 | Survodutide | |
|---|---|---|
| Highest evidence tier on the page | E3 Early human evidence Small, open-label, uncontrolled, case series, or a registered trial with no published results. | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. |
| Regulatory status | Preclinical (mouse studies only); not approved, no human trials | In clinical development, not approved |
| Research area | Longevity and mitochondrial, Metabolic and incretin | Metabolic and incretin |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | Not reliably established | C192H289N47O61, from a chemical supplier data sheet only, not confirmed against a peer-reviewed or regulatory source |
| Molar mass | Not reliably established | 4231.7, from a chemical supplier data sheet only, not confirmed against a peer-reviewed or regulatory source |
| CAS number | 210302-17-3 | 2805997-46-8, from vendor catalogues, and salt-form assignments in those catalogues are not reliable |
| Registered trials on this site | None linked yet | 14 in the tracker |
| What is not known | Everything about its effects, dosing, and safety in humans. BAM15 has never been administered to a human being in a published or registered trial. Whether its favorable mouse safety profile, relative to DNP, would translate to any degree of human safety margin. No such margin... | Whether survodutide raises energy expenditure in a human being. That is the central mechanistic claim made for the compound, it rests on rodent indirect calorimetry that reached significance at one dose on two days with no change in core temperature or activity, and it has... |
| Furthest registered phase | Not stated | Phase 3 |
| Trials currently active | Not stated | 2 |
| Trial sponsors | Not stated | Boehringer Ingelheim |
| Published trials covered on its page | Not stated | 7 |
| Amounts studied in those trials | Not stated | NCT04153929: Survodutide up to 0.3, 0.9, 1.8 or 2.7 mg once weekly, or 1.2 or 1.8 mg twice weekly, against placebo and open label semaglutide up to 1.0 mg once weekly for 16 weeks NCT04667377: Survodutide 0.6, 2.4, 3.6 or 4.8 mg once weekly, or placebo, 1:1:1:1:1 for 46 weeks, 20 weeks of escalation then 26 weeks of maintenance NCT04771273: Survodutide 2.4, 4.8 or 6.0 mg once weekly, or placebo, 1:1:1:1 for 48 weeks, 24 weeks of rapid escalation then 24 weeks of maintenance As reported on the compound page. Amounts are not comparable between compounds. |
Full pages: BAM15 and Survodutide. See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
